ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
25 5월 2023 - 5:05AM
ERYTECH Announces the Availability of the Documents for its Annual
General Meeting to be held on June 23, 2023
ERYTECH Announces the
Availability of the Documents for its Annual General Meeting to be
held on June 23,
2023
Cambridge, MA (U.S.) and Lyon
(France), May
24, 2023
– ERYTECH Pharma
(Nasdaq &
Euronext: ERYP), a
clinical-stage biopharmaceutical company
developing innovative therapies by encapsulating
therapeutic drug substances inside red blood
cells, today
announced the availability of the
documents for its Annual General Meeting to be held on
Friday, June 23,
2023.
ERYTECH’s shareholders are hereby informed of
the Annual General Meeting which will be held on June 23, 2023 at
09:30am CEST at the Hôtel Intercontinental, 2 rue Scribe, 75009
Paris (FRANCE).
Shareholders may participate in the General
Meeting as follows:
- Attend in person;
- Voting by mail or by internet on
the secure voting platform Votaccess; or
- Give a proxy to any individual or
legal entity of their choice, under the applicable legal and
regulatory conditions, or give a proxy to the Chairman of the
Shareholders' Meeting. The Chairman will then vote on their behalf
in favor of the adoption of the draft resolutions presented or
approved by the Board of Directors and against the adoption of all
other draft resolutions.
Availability of the documents for the
Shareholders’ Meeting
The notice of meeting including the agenda and
the draft resolutions, together with the principal details for
attending and voting at the Combined Shareholders’ Meeting was
published in the French Bulletin of Legal Announcements no. 59 on
May 17, 2023.
Shareholders have access to the preparatory and
information documents for the Shareholders’ Meeting as provided for
by law and the regulations. They may also be viewed on the Company
website at: https://investors.erytech.com/general-meeting.
Shareholders are kindly advised to consult this section on a
regular basis, as it may be updated to specify the final terms and
conditions of participation in this Shareholders’ Meeting, in
accordance with legal and regulatory requirements.
About ERYTECH:
www.erytech.com
ERYTECH is a biopharmaceutical company
developing innovative red blood cell-based therapeutics for severe
forms of cancer and orphan diseases. Leveraging its proprietary
ERYCAPS® platform, which uses a novel technology to encapsulate
drug substances inside red blood cells, ERYTECH is developing a
pipeline of product candidates for patients with high unmet medical
needs.
On February 15 2023, ERYTECH announced its
intended strategic combination with PHERECYDES to create a global
player in extended phage. More detail can be found in the press
release.
ERYTECH is listed on the Nasdaq Global Select
Market in the United States (ticker: ERYP) and on the Euronext
regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).
ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC
Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next
Biotech indexes.
For more information, please visit
www.erytech.com
CONTACTS
ERYTECH
Eric SoyerCFO & COO |
NewCapMathilde Bohin / Louis-Victor
DelouvrierInvestor relationsNicolas
MerigeauMedia relations |
+33 4 78 74 44
38investors@erytech.com |
+33 1 44 71 94 94
erytech@newcap.eu |
- PR_ERYTECH_2023 General Assembly_VF
Phaxiam Therapeutics (LSE:0QSS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Phaxiam Therapeutics (LSE:0QSS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024